In melanoma and NSCLC patients treated with PD-1 inhibitor therapy, serum levels of IL-8 decreased at the time of best response and serum levels rose in non-responders at the time of disease progression (90). The gene discussed is CXCL8; the disease is non-small cell lung carcinoma.